Tiziana Life Sciences PLC (TLSA) 宣布了新的生物标志物数据。数据显示，其鼻用候选药物Foralumab在伴有隐匿性残疾进展的非活动性继发进展型多发性硬化症患者中，能够下调脑脊液中的炎症反应，同时上调神经保护通路。此外，该药物的作用与正电子发射断层扫描所观察到的小胶质细胞活化减少存在相关性。
这些发现为Foralumab的治疗机制提供了新的见解。研究表明，该疗法可能通过调节中枢神经系统的免疫环境，为这类难治性多发性硬化症患者带来新的希望。
Tiziana Life Sciences PLC (TLSA) 宣布了新的生物标志物数据。数据显示，其鼻用候选药物Foralumab在伴有隐匿性残疾进展的非活动性继发进展型多发性硬化症患者中，能够下调脑脊液中的炎症反应，同时上调神经保护通路。此外，该药物的作用与正电子发射断层扫描所观察到的小胶质细胞活化减少存在相关性。
这些发现为Foralumab的治疗机制提供了新的见解。研究表明，该疗法可能通过调节中枢神经系统的免疫环境，为这类难治性多发性硬化症患者带来新的希望。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.